Indian Drugs and Pharmaceuticals Limited (IDPL) is an Indian state-owned pharmaceutical enterprise established by the Government of India to support the country's self-reliance in the manufacture of essential drugs and pharmaceutical formulations. It functioned under the administrative control of the Ministry of Chemicals and Fertilizers, Department of Pharmaceuticals.
| Name | Indian Drugs and Pharmaceuticals Limited (IDPL) |
|---|---|
| Type | Public sector undertaking (state-owned corporation) |
| Industry | Pharmaceuticals |
| Country | India |
| Owner | Government of India |
| Administrative ministry | Ministry of Chemicals and Fertilizers, Department of Pharmaceuticals |
In the years following independence, India relied heavily on imported bulk drugs and formulations. To reduce this dependence and to make essential medicines available at affordable prices, the Government of India set up a number of public sector pharmaceutical enterprises. IDPL was conceived as a flagship undertaking within this policy framework, intended to produce bulk drugs, antibiotics, synthetic drugs, and finished formulations on an industrial scale.
IDPL operated manufacturing units at multiple locations in India, producing a range of bulk drugs and formulations for the domestic market. The company also supplied medicines to government health programmes and public health institutions, and contributed to drug supplies during national emergencies and epidemics.
IDPL played an important role in shaping the Indian pharmaceutical industry during its formative decades. By developing indigenous manufacturing capability for bulk drugs that were previously imported, it helped lay the technical and human-resource base on which the wider Indian pharmaceutical sector later expanded. Trained personnel from IDPL went on to contribute to private and public sector drug manufacturing across the country.
Like several other older public sector undertakings, IDPL faced financial and operational difficulties in the post-liberalisation period as the Indian pharmaceutical market became increasingly competitive. The Government of India considered the company's status through various restructuring and disinvestment processes administered by the Department of Pharmaceuticals and related agencies.